Search

An abstract of the article "Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial," by I. J. Jacobs and colleagues is presented.

The article discusses a result of a study conducted by researchers in Spain on the effect of the Mediterranean diet in cardioprotection in which they reveals that the Mediterranean diet is helpful in decreasing risk for breast cancer.

The article presents multisite study which suggests that the addition of tomosynthesis improves screening performance over digital mammography and mentions the concerns regarding the screening mammography which includes diagnosis of ductal carcinoma in situ (DCIS).

The article discusses research by F. Mol on salpingotomy versus salpingectomy in women with tubal pregnancy published in the February 3, 2014 issue of "The Lancet."

The article discusses research on mammography and references two studies, including "Quantifying the Benefits and Harms of Screening Mammography" by H. G. Welch and H. J. Passow in the December 30, 2013 issue of "JAMA Internal Medicine."

The article discusses the bone health in women who had stopped taking menopausal hormone therapy referencing a study published in the November 2011 issue of "Menopause."

The article discusses research being done on the medical value of mammography by P. Autier et al, which appeared in the July 28, 2011 issue of the "British Medical Journal."

The article discusses a study, published in the August 2010 issue of "The New England Journal of Medicine," which found that screening mammography in women lowers breast cancer-related mortality.

The article presents a question and an answer on the reliability of Mammographic Assessment of Breast Density which is associated with risks of breast cancer with radiologists suggesting to nor image regularly breasts with dense breast tissues.

The article discusses a review and meta-analysis of several randomized trials about the efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in pre- and postmenopausal women and found that the treatment has marginal benefits and caused adverse events.

The article reports on the updated screening mammography guidance of the U.S. Preventive Services Task Force (USPSTF) for average-risk women.

The article presents a research on the impact of estrogen-progestin therapy and the risk for breast cancer with corresponding comment. Women's Health Initiative (WHI) released data on randomized trial for estrogen with progestin hormone therapy for breast cancer. The author said that result from the WHI are durable on whether breast cancer incidence with increase again after hormone therapy for women.

The author discusses the update on the 2003 guideline of the American Cancer Society (ACS) regarding the risks for women in mammography screening that includes the annual screening and optional screening while citing the decision to follow the U.S. Preventive Services Task Force (USPSTF) guidance on biennial screening starting at age 50.

The article reports on the approval of flibanserin by the U.S. Food and Drug Administration for treating premenopausal women with hypoactive sexual desire disorder (HSDD).

The article presents a comparison between venlafaxine and low-dose estradiol for hot flashes.

The article discusses the results of a study which confirmed that 22 percent of cancers identified with screening mammography were overdiagnosed breast tumors. It references a research published in the journal "Cochrane Database Systematic Reviews." The results include similar cumulative mortality from breast cancer among women in the mammography and no-mammography groups and suggestion for patients to follow the 2009 U.S. Preventive Services Task Force guidelines.

The article discusses a five-year follow-up research on the efficacy and safety of the aromatase inhibitor anastrozole, referencing the study "Anastrozole for Prevention of Breast Cancer in High-Risk Postmenopausal Women (IBIS-II)," by J. Cuzick and colleagues.

The article discusses a study which evaluated serial transvaginal ultrasonography and its use in monitoring ovarian anomalies published in the August 2013 issue of "Obstetrics & Gynecology."

The article discusses a study on the accessibility of ambulatory care for mobility-impaired patients which showed that most practices could not accommodate the patients on wheel chairs due to several reasons, adding that gynecology practices were the most likely to report inaccessibility.

The article offers information on a study that investigated the efficacy of anticholinergic agent and botulinum toxin on urgency urinary incontinence.

The article discusses the U.S. Preventive Services Task Force (USPSTF) advice against ovarian cancer screening, referencing the article "Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement" in the September 2012 "Annals of Internal Medicine."

The article focuses on a study conducted among randomized 120 women which aims to compare the effect of carbomer-free gel lubricant and water in reducing the pain during vaginal speculum examinations.

The article offers information on North American Menopause Society (NAMS) guidelines and discusses that many women received inappropriate screening and treatment.

The article reports that investigators, analyzing Nurses' Health Study data from 1980 to 2008, have found that low levels of alcohol consumption equivalent to 3-6 glasses of wine weekly leads to minimally but significantly elevated risk for breast cancer in women.

The article presents the Swedish study which examined the effectiveness of routine breast screening in preventing deaths due to breast cancer.

The article discusses research on ovarian cancer screening. It references the study "Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial," by S. S. Buys et al, published in the June 8, 2011 issue of "JAMA: The Journal of the American Medical Association." The findings indicated that screening based on serum cancer antigen (CA) 125 testing and vaginal ultrasound was not effective. Risks linked with follow-up of false-positive screening results are also noted.

The article discusses lengthened follow-up of Women's Health Initiative (WHI) to postmenopausal women with hysterectomies which reveals that estrogen has no significant effect on health outcomes and that the reduction in the risk for breast cancer still persists.

The article discusses a study that investigates the efficacy of selective serotonin reuptake inhibitor (SSRI) escitalopram (Lexapro) in the treatment of healthy menopausal women with vasomotor symptoms (VMS), as hormone therapy remains the only treatment approved by the Food and Drug Administration (FDA).

The article discusses research on the effects of estrogen-progestin hormone therapy on breast cancer mortality, referencing a study by R. T. Chlebowski and colleagues, published in the October 20, 2010 issue of the "Journal of the American Medical Association."

An abstract of the article "Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement," by the U.S. Preventive Services Task Force is presented.

The article discusses a study conducted in Israel that examined the safety of metoclopramide use during early pregnancy. Records of over 80,000 singleton births in the country were investigated. It is found that metoclopramide use was not associated with risk for congenital malformations, preterm delivery and perinatal death.

The article presents a study which compared screening mammography rates from 2001 through 2004 among women enrolled in Medicare plans requiring cost sharing versus those with full coverage for screening to assess the effect of cost sharing on preventive health services. In 2004, the proportion of women enrolled in cost-sharing Medicare plans rose from 0.5% in 2001 to 11.4% in 2004. The study found that rates of screening mammography were significantly higher with full coverage than with cost sharing.